Stockscreener 앱 받기
0.00
100.00%
-8.28
전일 마감가:
$8.28
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$413.12M
수익:
-
순이익/손실:
$-52.07M
주가수익비율:
0.00
EPS:
-0.2077
순현금흐름:
$-44.93M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
$0.00
$0.00
1주일 범위
$0.00
$0.00
52주 변동 폭
$0.00
$9.83
Cybin Inc Stock (CYBN) Company Profile
명칭
Cybin Inc
전화
908 764 8385
주소
100 King Street West, Suite 5600, Toronto
Compare CYBN vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CYBN
Cybin Inc
|
0.00 | 413.12M | 0 | -52.07M | -44.93M | -0.2077 |
VRTX
Vertex Pharmaceuticals Inc
|
436.58 | 111.05B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
758.32 | 79.01B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
795.76 | 50.08B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
313.02 | 41.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
300.87 | 34.67B | 5.36B | 287.73M | 924.18M | 2.5229 |
Cybin Inc Stock (CYBN) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-04-13 | 개시 | TD Cowen | Buy |
| 2026-02-02 | 개시 | Jefferies | Buy |
| 2025-03-13 | 개시 | Guggenheim | Buy |
| 2021-11-19 | 다운그레이드 | Maxim Group | Buy → Hold |
Cybin Inc 주식(CYBN)의 최신 뉴스
Robert Langer, who helped found Moderna, joins Helus Pharma board - Stock Titan
How Leadership Turnover at Helus Pharma Will Impact Cybin’s (HELP) Execution Narrative - simplywall.st
[SCHEDULE 13G/A] CYBIN INC. Amended Passive Investment Disclosure - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Cybin: Regulatory Tailwinds Unlock Asymmetric Upside (Rating Upgrade) (NASDAQ:HELP) - Seeking Alpha
Trump's Executive Order May Boost Psychedelic Stocks. Here Are 7 to Buy in 2026 - U.S. News Money
Cybin stands out as the most undervalued psychedelic stock as Trump signs on faster PTSD research - MSN
Helus Pharma CEO Michael Cola steps down at board’s request By Investing.com - Investing.com India
Helus Pharma CEO Michael Cola steps down; Eric So takes interim CEO role - MSN
Helus Pharma Backs U.S. Executive Order Accelerating Psychedelic Treatment Pathways - TipRanks
Helus Pharma (Nasdaq: CYBN) aligns late-stage NSA pipeline with U.S. psychedelic policy push - Stock Titan
Helus Pharma (CYBN) CEO steps down as co-founder Eric So becomes interim chief - Stock Titan
Psychedelic Stocks Surge After Executive Order, Focus on Compass Pathways (CMPS) - GuruFocus
Helus Pharma CEO Michael Cola steps down at board’s request - Investing.com
Helus Pharma Expresses Support for Executive Order Advancing Psychedelic Research and Regulatory Pathways for Serious Mental Health Conditions - The Manila Times
White House psychedelics push intersects with Helus Phase 3 depression drug - Stock Titan
Helus Pharma Announces CEO Changes Effective April 20, 2026 - marketscreener.com
Cybin Inc. Common Stock (HELP) - Minichart
Cybin Insider Ups Holding By 105% During Year - Yahoo Finance
HELP Options Chain — NASDAQ:HELP - TradingView
Millennium Management LLC Acquires Additional Shares in Helus Ph - GuruFocus
Psychedelic Stocks Tracker - Psychedelic Alpha
Helus Pharma (Nasdaq: HELP; CYBN) taps Dr. Ken Kramer to lead medical - Stock Titan
Helus Pharma Strengthens Medical Leadership by Appointing Dr. Ken Kramer as Senior Vice President, Medical Affairs - Investing News Network
Helus Pharma Taps Neuroscience Veteran Ken Kramer to Lead Medical Affairs - TipRanks
Cybin Inc (HELP) reports positive phase 2 anxiety study data - MSN
HELP Initiated Coverage by TD Cowen -- Price Target Set at $8 - GuruFocus
Cybin Inc. (NASDAQ:HELP) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Aug PostEarnings: What hedge funds are buying Cybin Inc2026 Historical Comparison & Daily Chart Pattern Signals - baoquankhu1.vn
Cybin (NASDAQ:HELP) Now Covered by TD Cowen - MarketBeat
Top Cybin (HELP) Competitors 2026 - MarketBeat
HELP: Cybin Inc.Brokerage Recommendations Chart - Zacks Investment Research
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
HELUS Pharma Reports Third Quarter Fiscal Year 2026 Financial Results and Recent Business Highlights - ADVFN
Millennium Group (CYBN) reports 2.51M shares, 5.0% stake - Stock Titan
Rate Cut: Will Cybin Inc stock recover after earningsRisk Management & Technical Pattern Based Signals - baoquankhu1.vn
Can Cybin (HELP) Stock Beat Estimates | Price at $5.33, Up 1.52%Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Aug Decliners: Does Cybin Inc stock have upside surprise potential2026 Short Interest & Weekly Breakout Watchlists - baoquankhu1.vn
Total non-current assets of Cybin, Inc. – NEO:HELP - TradingView — Track All Markets
Cybin Inc (NASDAQ:HELP) - intelligentinvestor.com.au
HELP Should I Buy - Intellectia AI
HELP Stock Price, Quote & Chart | CYBIN INC (NASDAQ:HELP) - ChartMill
Trend Recap: Is Cybin Inc on track to beat earningsTrade Entry Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Guidance Update: Can Cybin Inc be the next market leader2026 Analyst Calls & Accurate Entry and Exit Point Alerts - baoquankhu1.vn
Cybin Inc (CYBN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.32%
0.80%
자본화:
|
볼륨(24시간):